Here’s a summary of recent developments in the medicinal cannabis landscape in Austria:**Cantourage Group SE Partners with JACOBY GM to Supply THC-Based Products**In July 2023, Cantourage Group SE, a European cannabis producer and distributor, announced a partnership with JACOBY GM Pharma GmbH, a leading Austrian pharmaceutical wholesaler, to supply the Austrian market with THC-based medicinal products. This partnership marks Cantourage’s expansion into the Austrian market and strengthens its position in the European cannabis sector.**Austria Sees Record Imports of Medical Cannabis in 2021**According to Prohibition Partners, Austria saw a record high of medical cannabis imports in 2021. This increase can be attributed to growing patient demand and expanding regulatory frameworks.**Austrian Lawsuit Challenges Constitutionality of Cannabis Prohibition**In May 2023, a landmark case was filed at the Austrian Supreme Court challenging the constitutionality of the country’s cannabis prohibition law. The case highlights the ongoing debate surrounding cannabis legalization in Austria.**Austrian Chamber of Pharmacists Supports Medicinal Cannabis Use**The Austrian Chamber of Pharmacists has been a vocal advocate for the use of medicinal cannabis. In 2022, the Chamber released a position paper outlining the potential benefits of cannabis for various medical conditions.**Latest Regulatory Updates**In March 2023, the Austrian Ministry of Health classified hexahydrocannabinol (HHC) as a New Psychoactive Substance. HHC is a naturally occurring cannabinoid with psychoactive properties. This classification could impact the availability of HHC-based products in Austria.Overall, the medicinal cannabis landscape in Austria is evolving rapidly, with growing patient demand, expanding regulatory frameworks, and ongoing legal challenges. As the sector matures, we can expect to see further developments in Austria’s approach to medicinal cannabis.